Literature DB >> 24101313

Analysis of risk factors for recurrence of giant cell tumor of the sacrum and mobile spine combined with preoperative embolization.

Zhou Ming1, Chen Kangwu, Yang Huilin, Wang Genlin, Lu Jian, Ji Yiming, Wu Chunshen, Chen Chao.   

Abstract

AIM: To investigate the factors related to the local recurrence-free survival time (LRFS) after surgical treatment of GCT of the sacrum and mobile spine combined with preoperative embolization.
MATERIAL AND METHODS: We retrospectively reviewed 28 consecutive patients with GCT of the sacrum and mobile spine who underwent initial surgical excision combined with preoperative embolization between 1995 and 2011. Data regarding age, gender, tumor location, tumor size, tumor extension, radiation therapy, and local recurrences were reviewed and analyzed statistically.
RESULTS: All patients underwent intralesional resection. The average duration of follow-up was 86.4 months (range, 15 - 193 months). 8 (28.6%) patients developed local recurrence. The average recurrence time was 35.6 months (range, 5 - 79 months), and the local recurrence-free survival rates at 3 and 5 years were 89.1% and 75.5%, respectively. LRFS was found statistically longer in intracompartmental (T1) tumors as compared with extracompartmental (T2) tumors (P < 0.05), but not for age, gender, tumor location, tumor size, or radiation therapy.
CONCLUSION: Intralesional excision with preoperative embolization is a feasible choice for T1 tumors of the sacrum and mobile spine, but for T2 tumors, more aggressive treatment may be required. The choice of surgical treatment should be balanced between the complications and tumor recurrence.

Entities:  

Mesh:

Year:  2013        PMID: 24101313     DOI: 10.5137/1019-5149.JTN.7939-13.0

Source DB:  PubMed          Journal:  Turk Neurosurg        ISSN: 1019-5149            Impact factor:   1.003


  5 in total

1.  Expression of IMP3 and IGF2 in giant cell tumor of spine is associated with tumor recurrence and angiogenesis.

Authors:  K Zhang; M Zhou; H Chen; G Wu; K Chen; H Yang
Journal:  Clin Transl Oncol       Date:  2015-03-05       Impact factor: 3.405

Review 2.  Systematic Review and Meta-analysis of En Bloc Vertebrectomy Compared with Intralesional Resection for Giant Cell Tumors of the Mobile Spine.

Authors:  Panya Luksanapruksa; Jacob M Buchowski; Weerasak Singhatanadgige; David B Bumpass
Journal:  Global Spine J       Date:  2016-03-07

3.  Vertebral replacement for the treatment of vertebral osteosarcoma in a cat.

Authors:  Kohei Nakata; Harumi Miura; Hiroki Sakai; Takashi Mori; Sanae Shibata; Hidetaka Nishida; Sadatoshi Maeda; Hiroaki Kamishina
Journal:  J Vet Med Sci       Date:  2017-05-04       Impact factor: 1.267

4.  A nonrandomized controlled study of sacral giant cell tumors with preoperative treatment of denosumab.

Authors:  Yongkun Yang; Yuan Li; Weifeng Liu; Hairong Xu; Xiaohui Niu
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

5.  Prognosis and Risk Factors Influencing Recurrence in Surgery-treated Patients with Primary Sacral Tumors.

Authors:  Xiliang Dang; Liping Lian; Dongsheng Wu
Journal:  Iran J Public Health       Date:  2017-08       Impact factor: 1.429

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.